07:00 , Oct 20, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Colorectal cancer Apolipoprotein B mRNA editing enzyme catalytic polypeptide-like 3G (APOBEC3G) Mouse...
07:00 , May 27, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease HIV/AIDS Apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3G (APOBEC3G; A3G); IL-15; toll-like receptor 2 (TLR2);...
07:00 , Oct 9, 2008 |  BC Innovations  |  Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Infectious disease ...
07:00 , Apr 10, 2008 |  BC Innovations  |  Targets & Mechanisms

Putting Cancer to REST

Although previous work has shown that either increasing or decreasing the level of repressor element-1-silencing transcription factor can induce tumors, it was unclear how to go about targeting or modulating the zinc-finger DNA-binding protein. Two...
07:00 , Apr 9, 2007 |  BioCentury  |  Tools & Techniques

Unraveling ubiquitin complexity

Like kinases, ligases are a ripe target area. The difference is that ligases generally are harder to inhibit. Rigel Inc. thinks it achieved proof of principle in the ubiquitin ligase field for cancer a few...